What is Allogene Therapeutics?
Allogene Therapeutics is dedicated to pioneering the development and commercialization of genetically engineered allogeneic T cell therapies aimed at treating various forms of cancer. The company's pipeline includes UCART19 for R/R CD19 positive B-cell acute lymphoblastic leukemia, cemacabtagene ansegedleucel for large B-cell lymphoma, and ALLO-715 for R/R multiple myeloma. Allogene Therapeutics also has ongoing research into treatments for chronic lymphocytic leukemia, renal cell cancer, autoimmune diseases, and small cell lung cancer, among others. Its strategic collaborations with industry leaders like Pfizer and The University of Texas MD Anderson Cancer Center, alongside partnerships with Notch Therapeutics and Foresight Diagnostics, highlight its commitment to advancing innovative cancer therapies through robust research and development initiatives.
How much funding has Allogene Therapeutics raised?
Allogene Therapeutics has raised a total of $908M across 4 funding rounds:
Multiple Rounds
$708M
Stock/Share Issuance
$200M
Series A (2018): $300M with participation from Pfizer, Two River, TPG, the University of California Office of the Chief Investment Officer, Vida Ventures, and BellCo Capital
Series B (2018): $120M led by Fidelity Management and Research Company, venBio Select Advisor, Surveyor Capital, the University of California Office of the Chief Investment Officer, Perceptive Advisors, T. Rowe Price, Franklin Templeton Investments, Jennison Associates, and Deerfield
Stock Issuance/Offering (2018): $288M, investors not publicly disclosed
Stock/Share Issuance (2026): $200M, investors not publicly disclosed
Key Investors in Allogene Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company is a prominent financial services firm offering a wide array of investment, wealth management, and retirement planning solutions. They are known for supporting companies across various sectors through their extensive investment capabilities.
T. Rowe Price
T. Rowe Price is a global investment management firm founded in 1937, managing assets for individuals and institutions. They are recognized for their expertise in equity and fixed income markets, providing investment services worldwide.
Franklin Templeton Investments
Franklin Templeton is a global investment management organization with a long history, offering specialized investment capabilities across multiple asset classes. They provide a broad range of investment products and services to clients globally.
What's next for Allogene Therapeutics?
With the recent influx of $200M in strategic capital, Allogene Therapeutics is poised to accelerate its clinical development programs and expand its manufacturing capabilities. The company's focus on allogeneic CAR T cell therapies positions it at the forefront of a rapidly evolving field, offering potential off-the-shelf treatment options. Future growth will likely involve advancing its lead candidates through late-stage clinical trials, seeking regulatory approvals, and potentially forging new strategic alliances to broaden its therapeutic reach and solidify its market position in the competitive oncology landscape. The substantial enterprise-level backing provides a strong foundation for achieving these ambitious objectives.
See full Allogene Therapeutics company page
